October 25, 2021
Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for treatment of relapsing remitting (RRMS) and primary...
Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....
3 University Plaza Drive, Ste 116Hackensack, NJ 07601
© 2021 CMSC